← Leaderboards
Pietro Genovese
Dana-Farber Cancer Inst
$5,128,749
Attributed
$6,295,875
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2021–25$2.5M$1.9M$1.3M$625K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,295,875 · 4
By mechanism
R01$6,046,230 · 3
R21$249,645 · 1
Top collaborators
- Daniel Evan Bauer3 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Lee Marshall Nadler$396,612,225
- Luca Pinello$6,835,504
- Christian Brendel$1,241,366
- Alan David D'andrea$28,094,196
- Alessandra Biffi$1,098,714
Others in their field
Other Emerging Leaders on “Engineering”
- Lisa Garcia Bedolla · University Of California-Berkeley$175,927,128
- John E West · University Of Texas At Austin$131,399,667
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Peter K Fritschel · California Institute Of Technology$78,820,000
- Joy Williamson-Lott · University Of Washington$69,987,326
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$62,539,586
Research focus
EngineeringEngraftmentToxic EffectCellsResponseSpecificityPreservationHematopoietic Stem CellsAllogenicAffectTransplantationResearch Clinical TestingMedicalPhysiologicalValidationBase EditingCell TransplantationInnovationGenotoxicityHematologyGene TherapyHomologous TransplantationImmunotoxinsHematopoietic Stem Cell Transplantation
Grant awards (12)
Chemotherapy-free cure of hemoglobin disorders through base editing$766,048
R01 · FY2025 · HL
Multiplex Epitope Editing to Enable Novel Immunotherapies for Acute Myeloid Leukemia$721,888
R01 · FY2025 · CA · contact PI
Development, Optimization and Preclinical Modeling of Hematopoietic Stem Cell Gene Editing for the Treatment of RAG1 Immunodeficiency$442,500
R01 · FY2025 · AI · contact PI
Advanced Genetic Engineering to Unravel Tumor-Specific B Cell Responses$249,645
R21 · FY2025 · CA · contact PI
Multiplex Epitope Editing to Enable Novel Immunotherapies for Acute Myeloid Leukemia$780,389
R01 · FY2024 · CA · contact PI
Chemotherapy-free cure of hemoglobin disorders through base editing$760,457
R01 · FY2024 · HL
Development, Optimization and Preclinical Modeling of Hematopoietic Stem Cell Gene Editing for the Treatment of RAG1 Immunodeficiency$442,500
R01 · FY2024 · AI · contact PI
Chemotherapy-free cure of hemoglobin disorders through base editing$807,747
R01 · FY2023 · HL
Development, Optimization and Preclinical Modeling of Hematopoietic Stem Cell Gene Editing for the Treatment of RAG1 Immunodeficiency$442,500
R01 · FY2023 · AI · contact PI
Development, Optimization and Preclinical Modeling of Hematopoietic Stem Cell Gene Editing for the Treatment of RAG1 Immunodeficiency$1
R01 · FY2023 · AI · contact PI
Development, Optimization and Preclinical Modeling of Hematopoietic Stem Cell Gene Editing for the Treatment of RAG1 Immunodeficiency$441,100
R01 · FY2022 · AI · contact PI
Development, Optimization and Preclinical Modeling of Hematopoietic Stem Cell Gene Editing for the Treatment of RAG1 Immunodeficiency$441,100
R01 · FY2021 · AI · contact PI